OA01.03 Benmelstobart with Anlotinib plus Chemotherapy as First-line Therapy for ES-SCLC: A Randomized, Double-blind, Phase III Trial

Small-cell lung cancer (SCLC) is a recalcitrant malignancy. Despite immunochemotherapy showed promise with a 2-month overall survival (OS) benefits in extensive-stage SCLC (ES-SCLC), improving long-term survival remains an unmet need. Limited benefit might attribute to the complicated SCLC microenvironment, which is characterized by immunosuppression, angiogenesis and vascularization. Tumor microenvironment reprogramming and tumor vessel normalization could promote immune cell infiltration, obtaining synergistic effects with immunotherapy.